NT-501 is an investigational ocular implant that utilizes an encapsulated cell-based delivery system to deliver continuous ciliary neurotrophic factor.

The researchers found that the primary composite reactogenicity outcome was noninferior in the simultaneous vs the sequential group. (HealthDay News) — Reactogenicity is comparable for simultaneous ...

(HealthDay News) — The supply of health care professionals available to provide HIV care is expected to continue to decline over the next 5 years, according to research published in the ...

The researchers projected that more than 42,000 deaths could be averted annually, including more than 11,000 among those with type 2 diabetes, with expanded access. (HealthDay News) — Expanding access ...

Full results from the trial will be presented at an upcoming medical meeting. Topline results from a phase 3 trial show that tezepelumab statistically significantly reduced the size of nasal polyps ...

One year after reports of supply chain issues, 49% of reports in the US and 34% of reports in Canada were associated with ...

The FDA has issued a proposal to remove a common decongestant in over the counter products.

Credit: Journey Medical Corporation. The approval was supported by data from 2 randomized, double-blind, active- and ...

Increased relative risk for adverse events seen among those admitted during weeks with high versus low COVID-19 burden ...

Clear cell hidradenoma is a tumor that results from overgrowth of either eccrine or apocrine sweat glands. Lesions are most ...

HealthDay News — The prevalence of diabetes was 15.8% among US adults during August 2021 to August 2023, according to a November data brief published by the National Center for Health Statistics.

The Orphan Drug designation was supported by preclinical research and preliminary data from the dose escalation/expansion phase 1/2 trial.